The Partnership to Improve Patient Care (PIPC) recently submitted comments on the Institute for Clinical and Economic Review's (ICER) assessment of treatments for for Epstein-Barr virus positive post-transplant lymphoproliferative disease.
We are concerned that ICER has chosen not to include caregiver costs in its model, nor does the model reflect the reported results in the trial data ICER has chosen to use. Our letter also critizes ICER's use of discriminatory "value" assessments, namely the quality-adjusted life year (QALY) and the equal value of life year gained (evLYG).
"ICER’s assessments continue to rely on flawed metrics and dated constructs of cost-effectiveness," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to engage directly with patients and people with disabilities and amend its modeling choices to ensure their needs are met."
"ICER’s assessments continue to rely on flawed metrics and dated constructs of cost-effectiveness," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to engage directly with patients and people with disabilities and amend its modeling choices to ensure their needs are met."
| draft_icer_ptld_comments_final.pdf |
